Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095   10/07/2025
57,63 USD (+1,86%)
(+1,86%)   10/07/2025
Grafiek Halozyme Therapeutics Inc. Grafiek Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. in het nieuws

6 mei 2025 · Halozyme Raises 2025 Financial Guidance Ranges And Reports Strong First Quarter 2025 Results · Persbericht

5 mei 2025 · Halozyme to Participate in the BofA Securities 2025 Healthcare Conference · Persbericht

28 april 2025 · Halozyme to Report First Quarter 2025 Financial and Operating Results · Persbericht

28 april 2025 · Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) · Persbericht

24 april 2025 · Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation · Persbericht

11 april 2025 · Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy · Persbericht

9 april 2025 · European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility · Persbericht

7 april 2025 · European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer · Persbericht

31 maart 2025 · Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications · Persbericht

13 september 2024 · Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer · Persbericht

Profiel Halozyme Therapeutics Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Helen Torley

Werknemers: 452

Mijn selecties